Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysis
These findings did not identify any population-level benefit of triplet therapy that clearly exceeded predictions under an independent-action model, although synergistic effects at the individual-patient level cannot be excluded. These findings support selective or sequential treatment strategies to optimize the benefit-toxicity balance in appropriate patient populations.
Authors
- Kenji Tanabe
- Shugo Yajima
- Hiroyuki Sato
- Wei "Wayne'' Chen
- Hitoshi Masuda
- Hajime Tanaka
- Yosuke Yasuda
- Hiroshi Fukushima
- Yasuhisa Fujii
- Akihiro Hirakawa
- Soichiro Yoshida
Institutions
- Tokyo College of Music (JP)
- Tokyo Institute of Psychiatry (JP)
- Fourth People's Hospital of Sichuan Province (CN)
- Mount Fuji Research Institute (JP)
- The Cancer Institute Hospital (JP)
- YKK (Japan) (JP)
- National Cancer Center Hospital East (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1016/j.urolonc.2025.110990
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00